Literature DB >> 8604704

Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIb-IIIa receptors.

R Sreedhara1, I Itagaki, R M Hakim.   

Abstract

Bleeding and platelet dysfunction are prominent features of uremia. Sh ear-induced platelet aggregation (SIPA) involves the interaction of von Willebrand factor (vWF) with platelet membrane glycoproteins (GP) Ib and IIb-IIIa, the same receptor-ligand pair involved in in vivo adhesion and aggregation of platelets in the arterial circulation. We have used a modified rotational cone-plate viscometer to measure SIPA and calcium flux in platelets. Flow cytometric analysis of the surface expression of GP Ib and IIb-IIIa was performed using flourescein isothiocyanate-conjugated monoclonal antibodies CD42b and CD41a, respectively. Uremic patients showed decreased SIPA (controls, 43% +/- 2% [mean +/- SEM]; chronic renal failure patients, 36% +/- 3%; chronic hemodialysis patients, 26% +/- 2%; P < 0.001) along with a decrease in GP IIb-IIIa (controls, chronic renal failure patients, and chronic hemodialysis patients, 840 +/- 25, 649 +/- 42, 661 +/- 38 mean flourescence intensity, respectively; P < 0.0001). Glycoprotein Ib in uremic patients was not significantly different from normal. Chronic hemodialysis patients also demonstrated increased platelet-bound fibrinogen (P < 0.001) and platelet-bound vWF (p < 0.01). Calcium flux and thromboxane B(2) generation during SIPA of uremic platelets was normal. However, uremic plasma showed twice the normal concentration of vWF (P < 0.001) and sodium dodecyl sulfate agarose gel electrophoresis revealed the presence of fibrinogen fragments. Mixing experiments demonstrated an inhibitory effect of uremic plasma on SIPA of normal platelets (decreased from 39% +/- 3% at baseline to 31% +/- 3% after incubation in uremic plasma) along with an activation-independent increase in platelet-bound fibrinogen and platelet-bound vWF. When uremic platelets were incubated in normal plasma, their SIPA increased from 12% +/- 5% at baseline to 18% +/- 4% after incubation in normal plasma; (P = 0.002), although it did not return to normal. These results suggest that the uremic platelet dysfunction results from decreased GP IIb-IIa availability due to receptor occupancy by fibrinogen fragments (and possibly vWF fragments).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8604704     DOI: 10.1016/s0272-6386(96)90358-3

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  6 in total

Review 1.  Future research directions to improve fistula maturation and reduce access failure.

Authors:  Haidi Hu; Sandeep Patel; Jesse J Hanisch; Jeans M Santana; Takuya Hashimoto; Hualong Bai; Tambudzai Kudze; Trenton R Foster; Jianming Guo; Bogdan Yatsula; Janice Tsui; Alan Dardik
Journal:  Semin Vasc Surg       Date:  2016-08-26       Impact factor: 1.000

Review 2.  Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonists in renal failure.

Authors:  B S Smith; P J Gandhi
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

Review 3.  Oral antiplatelet drugs in patients with chronic kidney disease (CKD): a review.

Authors:  Homam Ibrahim; Sunil V Rao
Journal:  J Thromb Thrombolysis       Date:  2017-05       Impact factor: 2.300

4.  Relationship between biomarkers and subsequent bleeding risk in ST-segment elevation myocardial infarction patients treated with paclitaxel-eluting stents: a HORIZONS-AMI substudy.

Authors:  Wouter J Kikkert; Bimmer E Claessen; Gregg W Stone; Roxana Mehran; Bernhard Witzenbichler; Bruce R Brodie; Jochen Wöhrle; Adam Witkowski; Giulio Guagliumi; Krzysztof Zmudka; José P S Henriques; Jan G P Tijssen; Elias A Sanidas; Vasiliki Chantziara; Ke Xu; George D Dangas
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

5.  A hypothesis-generating study to evaluate platelet activity in diabetics with chronic kidney disease.

Authors:  Donald F Brophy; Rika J Martin; Todd Wb Gehr; Marcus E Carr
Journal:  Thromb J       Date:  2005-03-29

6.  Elevated levels of procoagulant plasma microvesicles in dialysis patients.

Authors:  James O Burton; Hassan A Hamali; Ruchir Singh; Nima Abbasian; Ruth Parsons; Amit K Patel; Alison H Goodall; Nigel J Brunskill
Journal:  PLoS One       Date:  2013-08-02       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.